Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS) – ClinicalKey
There was an error loading this content. Please refresh the page to try again, or contact us if you continue to experience problems. BackgroundOrismilast is a novel oral phosphodiesterase-4 (PDE4) B/D inhibitor being investigated as a potential treatment for moderate-to-severe psoriasis. ObjectiveTo evaluate efficacy and safety of orismilast modified-release formulation in…